Represented Oppenheimer & Co. Inc, as sales agent, in connection with an $8.4 million at-the-market offering for OncoSec Medical Incorporated (Nasdaq: ONCS).

Represented ROTH Capital Partners, LLC, as exclusive underwriter, in connection with a public offering for EnSync, Inc., dba EnSync Energy Systems (NYSEMKT: ESNC).

Represented Rodman & Renshaw, a unit of H.C. Wainwright & Co., as the exclusive placement agent, in connection with a $10 million public offering for EyeGate Pharmaceuticals, Inc. (Nasdaq: EYEG).

Represented DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) in connection with a $9 million public offering.

Represented Laidlaw & Co., as placement agent, in connection with a $7 million private placement for Cooltech Holding Corp.

Represented Matinas BioPharma Holdings, Inc. (NYSEMKT: MTNB) in connection with its $30 million at-the-market offering.

Represented Maxim Merchant Capital, a division of Maxim Group LLC, as sole placement agent, in connection with a private offering for Virtual Health Partners, Inc.

Represented Provention Bio, Inc. in connection with a $28.4 million private placement.

Represented Maxim Merchant Capital, a division of Maxim Group LLC, as sole placement agent, in connection with a $25 million private offering for Diffusion Pharmaceuticals, Inc. (Nasdaq: DFFN).

Represented Special Situations Funds, as lead investor, in connection with a $15 million private placement in Ideal Power Inc.

Represented Presbia PLC (Nasdaq: LENS) in connection with a $10.8 million rights offering.

Represented Arch Therapeutics, Inc. (OTCQB: ARTH) in a $6.1 million registered direct offering.

Represented Aytu BioScience, Inc. (OTCQX: AYTU) in a warrant tender offer.

Represented CytoDyn Inc. (OTCQB: CYDY) in a registered direct offering.

Represented Motus GI Holdings, Inc., in connection with its $30 million private placement.

Represented Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) in connection with a $27.2 million registered direct offering.

Represented Aegis Capital Corp., as sole underwriter, in connection with a public offering for xG Technology, Inc. (Nasdaq: XGTI).

Represented Matinas BioPharma Holdings, Inc. (NYSEMKT: MTNB) in connection with a $13.5 million warrant tender offer.

Represented Malvern Bancorp, Inc. in its private placement of $25 million in aggregate principal amount of fixed-to-floating rate subordinated notes to certain institutional investors.

Represented Lakeland Bancorp, Inc. in its public offering of $75 million in aggregate principal amount of fixed-to-floating rate subordinated notes.

Represented Lakeland Bancorp, Inc. in the sale of $50 million of its common stock through an at-the-market equity offering.

Represented Oppenheimer & Co. Inc. which acted as the representative for the initial purchasers in Akoustis Technologies, Inc.’s (NASDAQ: AKTS) $15 million Rule 144A offering of 6.5% Convertible Senior Secured Notes.

Centivo, a new type of self-funded health plan, in its $34 million Series A financing led by Bain Capital Ventures, with additional investments from F-Prime Capital Partners, Maverick Ventures, Bessemer Venture Partners, Ingleside Investors, Rand Capital, Grand Central Tech Ventures, and Oxeon Investments.

Perch, the marketplace for buying and selling homes, in its $30 million Series A financing led by FirstMark Capital, with Juxtapose and Accomplice also participating in the round.

Aetion, the software platform company delivering the real-world analytics and evidence needed for biopharma and payers to engage in value-based care, in its $36.4 million Series B financing, in a round led by New Enterprise Associates (NEA) and including, as a new investor, Amgen Ventures, alongside existing investors Flare Capital Partners, Lakestar, and Oxeon Ventures. We previously represented Aetion in is $11.2 million Series A financing led by Flare Capital Partners and joined by Lakestar.